AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27031726 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral tDCS over the temporal-parietal region with right anode/left cathode configuration
Number of subjects: 13
Study 27031726 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral tDCS over the temporal-parietal region with right cathode/left anode configuration
Number of subjects: 13
Study 27031726 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 13
Study 25912854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics (clindamycin or first-generation cephalosporin) for 2 to 4 days followed by oral antibiotics for 20 to 30 days
Number of subjects: 14
Study 25912854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics (clindamycin or first-generation cephalosporin)
Number of subjects: 14
Study 25912854 — intervention group
Group type: EXPERIMENTAL
Intervention: Open incisional trepanation (trephination)
Number of subjects: 14
Study 25912854 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone biopsy for bacteriology
Number of subjects: 14
Study 23090007 — intervention group
Group type: EXPERIMENTAL
Intervention: No-overlap condition (high fluency salience)
Number of subjects: 31
Study 23090007 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap condition (low fluency salience)
Number of subjects: 31
Study 23090007 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study 20698383 — intervention group
Group type: EXPERIMENTAL
Intervention: Proctored simulator training (human expert feedback plus simulator feedback)
Number of subjects: 13
Study 20698383 — intervention group
Group type: COMPARATOR
Intervention: Independent simulator training (automated simulator feedback only)
Number of subjects: 13
Study 18215665 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 96
Study 18215665 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 96
Study 18215665 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 96
Study 16770746 — intervention group
Group type: EXPERIMENTAL
Intervention: SIPA (integrated service model)
Number of subjects: 1230
Study 16770746 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1230
Study 14725657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerosing foam (polidocanol 3% solution, 2.0 or 2.5 mL injection)
Number of subjects: 88
Study 14725657 — intervention group
Group type: COMPARATOR
Intervention: Sclerosing liquid (polidocanol 3% solution, 2.0 or 2.5 mL injection)
Number of subjects: 88
Study 14725657 — intervention group
Group type: COMPARATOR
Intervention: Sclerosing liquid
Number of subjects: 88
Study 14725657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerosing foam
Number of subjects: 88
Study 14725657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerosing foam and liquid
Number of subjects: 88
Study 16464192 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection strategies
Number of subjects: 0
Study 16464192 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining different collection methods
Number of subjects: 0
Study 16464192 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxies to collect resource utilization estimates
Number of subjects: 0
Study 16464192 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-reported data
Number of subjects: 0
Study 16464192 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of collecting data
Number of subjects: 0
Study 8838703 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 352
Study 8838703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 1594260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 10
Study 1594260 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 10
Study 30071830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports Stars intervention (eight, one-hour, weekly physiotherapy group sessions)
Number of subjects: 60
Study 30071830 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study 26443600 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-balloon technique (AB)
Number of subjects: 26
Study 26443600 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel-filling technique (GF)
Number of subjects: 26
Study 26443600 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 26
Study 24845165 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine taper (4-week duration)
Number of subjects: 10
Study 23758302 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based intervention (CBI)
Number of subjects: 397
Study 23758302 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist and computer-based intervention (T+CBI)
Number of subjects: 397
Study 23758302 — intervention group
Group type: COMPARATOR
Intervention: Control group (resource brochure only)
Number of subjects: 397
Study 21169166 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (n = 88)
Number of subjects: 263
Study 21169166 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based problem-solving therapy (n = 88)
Number of subjects: 263
Study 21169166 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (n = 87)
Number of subjects: 263
Study 18280042 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (cholinergic antagonist)
Number of subjects: 0
Study 18280042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16173650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon (16 mg)
Number of subjects: 375
Study 16173650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon (64 mg)
Number of subjects: 375
Study 16173650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon (16 or 64 mg)
Number of subjects: 375
Study 16173650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 12930012 — intervention group
Group type: EXPERIMENTAL
Intervention: Dayquil/Nyquil (D/N group)
Number of subjects: 120
Study 12930012 — intervention group
Group type: COMPARATOR
Intervention: Actifed DM plus paracetamol (ADM/P group)
Number of subjects: 120
Study 10830792 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0
Study 10830792 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study 8889742 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic index (HGI) meal
Number of subjects: 6
Study 8889742 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index (LGI) meal
Number of subjects: 6
Study 8889742 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Con) meal
Number of subjects: 6
Study 1509578 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem ICON HCG-urine
Number of subjects: 0
Study 1509578 — intervention group
Group type: COMPARATOR
Intervention: OPCO One-step Pacific Biotech
Number of subjects: 0
Study 6378810 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOL + P (leg CHO loading followed by 60-min arm exercise and a 24-h CHO-poor diet)
Number of subjects: 7
Study 6378810 — intervention group
Group type: COMPARATOR
Intervention: CHOL (leg CHO loading only)
Number of subjects: 7
Study 31138731 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenil pressurized metered‐dose inhaler (pMDI; 250 μg) with spacer
Number of subjects: 12
Study 31138731 — intervention group
Group type: EXPERIMENTAL
Intervention: Qvar Easi‐Breathe inhaler (100 μg) with spacer
Number of subjects: 12
Study 31138731 — intervention group
Group type: COMPARATOR
Intervention: Clenil pMDI without spacer
Number of subjects: 12
Study 31138731 — intervention group
Group type: COMPARATOR
Intervention: Qvar Easi‐Breathe inhaler without spacer
Number of subjects: 12
Study 31138731 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-rinsed spacers
Number of subjects: 12
Study 31138731 — intervention group
Group type: COMPARATOR
Intervention: Rinsed spacers
Number of subjects: 12
Study 29228091 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 150 mg/m2 days 1 and 15 Q28 (arm A)
Number of subjects: 258
Study 29228091 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/m2 days 1, 8 and 15 Q28 (arm B)
Number of subjects: 258
Study 29228091 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 75 mg/m2 days 1, 8, 15 and 22 Q28 (arm C)
Number of subjects: 258
Study 29228091 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) evaluation
Number of subjects: 258
Study 29228091 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade ≥2 sensory neuropathy
Number of subjects: 258
Study 27212028 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 1400
Study 27212028 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT
Number of subjects: 1400
Study 27212028 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month DAPT (acute coronary syndrome)
Number of subjects: 1400
Study 27212028 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT (acute coronary syndrome)
Number of subjects: 1400
Study 27212028 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month DAPT (diabetes mellitus)
Number of subjects: 1400
Study 27212028 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT (diabetes mellitus)
Number of subjects: 1400
Study 24713125 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning continuing education program
Number of subjects: 200
Study 24713125 — intervention group
Group type: COMPARATOR
Intervention: comparison group (control)
Number of subjects: 200
Study 22492249 — intervention group
Group type: EXPERIMENTAL
Intervention: New gel medical device (Proctoial) containing hyaluronic acid, tea tree oil, and methyl-sulfonyl-methane
Number of subjects: 36
Study 22492249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 21416034 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention training health workers to train community-based women groups in recognizing malaria symptoms and providing first-line treatment.
Number of subjects: 1715
Study 21416034 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 1715
Study 21416034 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups.
Number of subjects: 1715
Study 17040305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (OND) 0-60 microg.kg(‐1)
Number of subjects: 240
Study 17040305 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MET) 0-400 microg.kg(‐1)
Number of subjects: 240
Study 17040305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 0-500 microg.kg(‐1)
Number of subjects: 240
Study 17040305 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of OND and MET
Number of subjects: 240
Study 17040305 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with OND, MET, and DEX
Number of subjects: 240
Study 17040305 — intervention group
Group type: EXPERIMENTAL
Intervention: Children older than 7 years
Number of subjects: 240
Study 12968984 — intervention group
Group type: COMPARATOR
Intervention: Omapatrilat 2.5 mg (single dose)
Number of subjects: 0
Study 12968984 — intervention group
Group type: COMPARATOR
Intervention: Omapatrilat (multiple doses: 10, 25, 50, 75, or 125 mg daily for 10 days)
Number of subjects: 0
Study 12968984 — intervention group
Group type: COMPARATOR
Intervention: Omapatrilat (single dose)
Number of subjects: 0
Study 12968984 — intervention group
Group type: COMPARATOR
Intervention: Omapatrilat (single and multiple doses)
Number of subjects: 0
Study 12968984 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat (multiple doses)
Number of subjects: 0
Study 12968984 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat (doses > 7.5 mg)
Number of subjects: 0
Study 11460276 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush with 9,048 ppm fluoride as sodium fluoride
Number of subjects: 12
Study 9760791 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (Tilade-8 mg/24 hours)
Number of subjects: 10
Study 9760791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8473654 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 20
Study 8473654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3838321 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride with iron (300 mg ferrous sulfate)
Number of subjects: 16
Study 3838321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride with iron (300 mg ferrous sulfate)
Number of subjects: 16
Study 3838321 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride with milk
Number of subjects: 16
Study 3838321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride with milk
Number of subjects: 16
Study 3838321 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride with food
Number of subjects: 16
Study 3838321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride with food
Number of subjects: 16
Study 30457915 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) over the left lateral frontopolar cortex (FPC)
Number of subjects: 0
Study 30457915 — intervention group
Group type: COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS) over a posterior control site
Number of subjects: 0
Study 30457915 — intervention group
Group type: COMPARATOR
Intervention: No rTMS (baseline)
Number of subjects: 0
Study 27599667 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg
Number of subjects: 90
Study 27599667 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine 10 mg
Number of subjects: 90
Study 27599667 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 90
Study 25824259 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin (0.5%) administered as one drop four times at 15-minute intervals starting 75 minutes before surgery.
Number of subjects: 42
Study 25824259 — intervention group
Group type: COMPARATOR
Intervention: Oral moxifloxacin (400 mg) administered as a single tablet 12 hours before surgery.
Number of subjects: 42
Study 24024773 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (retinyl palmitate 25,000 IU/d)
Number of subjects: 84
Study 21346614 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg/d)
Number of subjects: 30
Study 21346614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19296254 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycoside of Tripterygium wilfordii (GTW)
Number of subjects: 39
Study 19296254 — intervention group
Group type: COMPARATOR
Intervention: SASP (sulfasalazine)
Number of subjects: 39
Study 17306507 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 61
Study 17306507 — intervention group
Group type: COMPARATOR
Intervention: Brief Nutritional Education (Control)
Number of subjects: 61
Study 15040502 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen breathing (FIO2 = 1.0, PIO2 = 460 mm Hg)
Number of subjects: 15
Study 15040502 — intervention group
Group type: COMPARATOR
Intervention: Ambient-air breathing (PIO2 = 86 mm Hg)
Number of subjects: 15
Study 12126263 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.6 mg o.d.
Number of subjects: 154
Study 12126263 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg o.d.
Number of subjects: 154
Study 12126263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 9651560 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g cholestyramine
Number of subjects: 2036
Study 9651560 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g cholestyramine and 20 mg pravastatin
Number of subjects: 2036
Study 9651560 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pravastatin
Number of subjects: 2036
Study 9651560 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pravastatin
Number of subjects: 2036
Study 9651560 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin and cholestyramine
Number of subjects: 2036
Study 9651560 — intervention group
Group type: EXPERIMENTAL
Intervention: cholestyramine
Number of subjects: 2036
Study 9651560 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 2036
Study 9651560 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin
Number of subjects: 2036
Study 9638202 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH, beta-endorphin, and cortisol secretion profiles measured on the second day after trauma
Number of subjects: 12
Study 9638202 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH and beta-endorphin secretion profiles
Number of subjects: 12
Study 9638202 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol secretion profile
Number of subjects: 12
Study 2693326 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 2693326 — intervention group
Group type: EXPERIMENTAL
Intervention: Oophorectomy (in premenopausal patients)
Number of subjects: 0
Study 2693326 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide or progestins (in postmenopausal patients)
Number of subjects: 0
Study 2693326 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endocrine therapy (Tamoxifen with prednisolone or androgens)
Number of subjects: 0
Study 342319 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 log EID50/dose
Number of subjects: 150
Study 342319 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 log EID50/dose
Number of subjects: 150
Study 342319 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 log EID50/dose (twice vaccinated)
Number of subjects: 150
Study 342319 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 log EID50/dose (twice vaccinated)
Number of subjects: 150
Study 342319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 31043770 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 µg/mL dexmedetomidine with 0.1% ropivacaine
Number of subjects: 80
Study 31043770 — intervention group
Group type: COMPARATOR
Intervention: 0.5 µg/mL sufentanil with 0.1% ropivacaine
Number of subjects: 80
Study 28624698 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-min analogue mindfulness intervention (present moment attention and awareness training; PMAA)
Number of subjects: 104
Study 28624698 — intervention group
Group type: COMPARATOR
Intervention: Coping-as-usual control condition
Number of subjects: 104
Study 25446221 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI breakfast with exercise
Number of subjects: 42
Study 25446221 — intervention group
Group type: COMPARATOR
Intervention: Low GI breakfast with resting
Number of subjects: 42
Study 25446221 — intervention group
Group type: COMPARATOR
Intervention: High GI breakfast with resting
Number of subjects: 42
Study 25446221 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI breakfast with exercise
Number of subjects: 42
Study 25446221 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI breakfast (regardless of exercise)
Number of subjects: 42
Study 24169411 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention (increasing community and liquor licensees' awareness, police activity, and feedback)
Number of subjects: 20
Study 24169411 — intervention group
Group type: COMPARATOR
Intervention: Control communities (no intervention)
Number of subjects: 20
Study 21697824 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 receptor blockade (sulpiride (SULP) 400 mg)
Number of subjects: 12
Study 19681862 — intervention group
Group type: EXPERIMENTAL
Intervention: R-salbutamol cream 0.5%
Number of subjects: 37
Study 19681862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 17116177 — intervention group
Group type: EXPERIMENTAL
Intervention: North American Caucasians (NAC)
Number of subjects: 4360
Study 15515991 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based communication system
Number of subjects: 1038
Study 15515991 — intervention group
Group type: COMPARATOR
Intervention: Control group (physicians not using the Web-based communication system)
Number of subjects: 1038
Study 11291689 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-ACT detection
Number of subjects: 907
Study 9174311 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block using 10mL of 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 0
Study 9174311 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block
Number of subjects: 0
Study 9174311 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous saline (control)
Number of subjects: 0
Study 8175117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 265
Study 8175117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg b.i.d.
Number of subjects: 265
Study 3288523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg twice daily for under 5-year-olds, 2 mg twice daily for others)
Number of subjects: 37
Study 3288523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31856493 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse yellow laser (SMYL) and intravitreal aflibercept injection (IAI) combination therapy
Number of subjects: 56
Study 31856493 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal aflibercept injection (IAI) monotherapy
Number of subjects: 56
Study 29847184 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program (4 sessions over 4 weeks)
Number of subjects: 18
Study 28615214 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 453
Study 28615214 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 453
Study 24675241 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic cholecystectomy (SPLC)
Number of subjects: 40
Study 24675241 — intervention group
Group type: COMPARATOR
Intervention: Classical four-port laparoscopic cholecystectomy (CLC)
Number of subjects: 40